November 4, 2014—Cardinal Health announced that its MynxGrip vascular closure device received US Food and Drug Administration approval for use to close femoral veins. The MynxGrip device is now indicated for use to seal 5-F, 6-F, and 7-F femoral arterial and femoral venous access sites. The MynxGrip device is intended to reduce times to hemostasis and ambulation, thereby potentially shortening postprocedure recovery times, stated the company.
The International Carotid Stenting Study (ICSS) randomised trial has reported the long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis in The Lancet, online ahead of print, on 14 October.
There is a compelling case for the medical community, including the device industry, to develop specific devices that are appropriate for paediatric patients. Paediatric interventional radiologists often have to “make do” and be creative in order to treat children whilst using devices that are designed for and tested on adults only. The need for appropriate devices for the paediatric population ranges from the common and simple, such as long-term feeding tubes and vascular access devices, to the expensive and biomechanically complex, such as bioabsorbable stent-grafts, say opinion leaders in the field.
The 12-month results of the study, presented at CIRSE 2014, demonstrated that new microwave technology can achieve a substantial rate of complete necrosis of liver metastases, even in a short-term treatment with few major complication
Terumo Europe has announced the creation of an Interventional Oncology division that will be active as of 1 April 2015. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states
Ablative Solutions has announced that the first patient in the Peregrine Study has been treated with company’s the investigational Peregrine system, which delivers agents directly to the sympathetic-nerve-laden peri-adventitial area of the renal artery to perform chemical neurolysis. Wojtek Wojakowski is the principal investigator of the study, and the patient has now been discharged from the hospital
Hansen has announced the completion of the first robot-assisted uterine fibroid embolization in the USA. Sandeep Rao, interventional radiologist, performed the procedure at Sierra Medical Center in El Paso, Texas, using the Magellan Robotic System
The company has announced that commercial cases were performed at The University Hospital, Leuven, Belgium, where Geert Maleux successfully treated two patients with the EOS device
Medtronic announced on 10 October 2014 the executive team who will lead the combined organisation following the close of its proposed acquisition of Covidien. The new company will be comprised of four major business groups and four geographic regions led by a new Executive Committee. Omar Ishrak will remain as chairman and chief executive officer of the new company, Medtronic plc.
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE study.
Ethicon has announced results of a large, retrospective study that showed the use of the Surgicel family of topical absorbable haemostats was associated with lower costs, reduced product usage, shortened length of hospital stay, and reduced transfusions compared to the use of other adjunctive haemostats. The study was presented at the Society for the Advancement of Blood Management annual meeting in Houston, Texas, USA.
Andre Bouhasin, an interventional cardiologist with West County Heart and Vascular Diagnostics, St Louis, Missouri, USA, used a novel device to remove blood clots and emboli from a protective filter and native arteries to restore blood flow in a patient s leg.
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer endorse radioembolisation, specifically with yttrium-90 (Y90) resin microspheres, as a clinically proven technology to “prolong time to liver tumour progression” in patients who have failed to respond to available chemotherapy options.
The ALN inferior vena cava filter has been available in the European market for over a decade. Following US FDA approval a few centres in the USA have gained extensive experience with this filter. A retrospective study reporting intermediate-term experience from the University of Texas Medical was presented at CIRSE 2014.
BTG has announced that it will begin selling its drug-eluting bead and embolization products, DC Bead and Bead Block, directly to physicians in 11 European countries from 1 April 2015. These products, developed and manufactured by BTG, are currently sold in Europe by the Terumo Corporation under a contract that expires on 31 March 2015.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos